| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c03a22433e751cab89b337125e7f0833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22fb477a4262cd498b0f49158f0af11a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate |
2018-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56dc870c958d969a9e0474899c0c94c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe71a919fb9bb1115c84655b6c2f94b7 |
| publicationDate |
2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018204721-A1 |
| titleOfInvention |
Methods and compositions for improving eye health |
| abstract |
Provided herein are anti-aging compositions and methods for maintaining and/or improving eye health in a subject, comprising administering to the eye of the subject a therapeutically effective amount of a compound that modulates the ATP-sensitive K+ channel and a pharmaceutically acceptable carrier. A method of treating glaucoma in a patient, comprising: obtaining a biological sample from the patient; testing the biological sample for presence of a mutation in Kir6.2 protein or KCNJ11 gene; and provided that the biological sample tests positive for the presence of a mutation in Kir6.2 protein or KCNJ11 gene, administering to the patient a therapeutically effective amount of a compound that specifically inhibits the Kir6.2 ATP-sensitive K+ channel and a pharmaceutically acceptable carrier. |
| priorityDate |
2017-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |